APLT - Applied Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
41.70
+0.72 (+1.76%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close40.98
Open40.94
Bid0.00 x 800
Ask0.00 x 1000
Day's Range40.19 - 42.11
52 Week Range7.95 - 57.39
Volume82,093
Avg. Volume241,708
Market Cap772.768M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.90
Earnings DateNov 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.67
  • GlobeNewswire

    Applied Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

    Applied Therapeutics, Inc. (APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at the Cowen and Company 40th Annual Health Care Conference on Tuesday, March 3, 2020 at 11:20 a.m. ET in Boston. Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, AT-007, is a novel central nervous system penetrant aldose reductase inhibitor (ARI) for the treatment of Galactosemia, a rare pediatric metabolic disease.

  • The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis
    Zacks

    The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis

    The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis

  • US Dollar Flexes Muscles Against Other Currencies: 5 Winners
    Zacks

    US Dollar Flexes Muscles Against Other Currencies: 5 Winners

    The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.

  • GlobeNewswire

    Applied Therapeutics, Inc. Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares of Common Stock

    Applied Therapeutics, Inc. (APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it has completed its public offering of 3,152,712 shares of its common stock. The Company intends to use the net proceeds from this offering, together with its existing cash and cash equivalents, to advance AT-007 for the treatment of Galactosemia including pre-launch activities and preparing for a potential commercial launch, to fund clinical development of AT-001 for treatment of Diabetic Cardiomyopathy as well as pre-launch activities, to advance AT-003 for the treatment of diabetic retinopathy through a planned Phase 1 clinical trial; to further develop its pipeline, including other candidates, formulations and derivatives, and to fund other research and development activities, working capital and other general corporate purposes.

  • Benzinga

    The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 23) Baudax Bio Inc (NASDAQ: BXRX ) Mesoblast limited (NASDAQ: ...

  • GlobeNewswire

    Applied Therapeutics, Inc. Announces Upsizing and Pricing of Public Offering of 2,741,489 Shares of Common Stock

    Applied Therapeutics, Inc. (APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the pricing of its public offering of 2,741,489 shares of its common stock, par value $0.0001 per share, at a price to the public of $45.50 per share. The gross proceeds to the Company from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, are expected to be approximately $124.7 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 411,223 shares of common stock at the price to the public, less underwriting discounts and commissions.

  • Benzinga

    The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 21) Abbott Laboratories (NYSE: ABT ) Apellis Pharmaceuticals ...

  • GlobeNewswire

    Applied Therapeutics, Inc. Announces Offering of 1,750,000 Shares of Common Stock

    Applied Therapeutics, Inc. (APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it plans to make a public offering of 1,750,000 shares of its common stock, par value $0.0001 per share, in an underwritten registered public offering. The Company expects to grant the underwriters a 30-day option to purchase up to 262,500 additional shares of common stock. The Company intends to use the net proceeds from this offering, together with its existing cash and cash equivalents, to advance AT-007 for the treatment of Galactosemia including pre-launch activities and preparing for a potential commercial launch, to fund clinical development of AT-001 for treatment of Diabetic Cardiomyopathy as well as pre-launch activities, to advance AT-003 for the treatment of diabetic retinopathy through a planned Phase 1 clinical trial; to further develop its pipeline, including other candidates, formulations and derivatives, and to fund other research and development activities, working capital and other general corporate purposes.

  • Applied Therapeutics Shares March Higher, Can It Continue?
    Zacks

    Applied Therapeutics Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor Applied Therapeutics.

  • Applied Therapeutics Up on Positive Galactosemia Study Data
    Zacks

    Applied Therapeutics Up on Positive Galactosemia Study Data

    Applied Therapeutics (APLT) soars on positive top-line results from the mid-stage study in adult Galactosemia patients on pipeline candidate, AT-007.

  • Company News for Jan 9, 2020
    Zacks

    Company News for Jan 9, 2020

    Companies In The News Are: LTHM, NEWA, APLT, WBA

  • Benzinga

    The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results

    The following is a roundup of top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 8.) Allergan plc (NYSE: AGN ):  AbbVie Inc ...

  • MarketWatch

    Applied Therapeutics' stock is up on mid-stage results for metabolic drug

    Shares of Applied Therapeutics Inc. jumped 27% in premarket trading on Wednesday after the company said it had positive results from a Phase-2 clinical trial testing AT-007 as a treatment for a rare metabolic disorder. The study found a reduction in plasma galactitol in adults with galactosemia taking the investigational drug, compared to those taking placebo. The company said it plans to seek regulatory approval in the second half of 2020. The therapy has an orphan-drug designation. Applied Therapeutics' stock is up 149% over the last three months, compared to the S&P 500 , which has gained 10% over the same time period. The ACTION-Galactosemia data presented today is our first pivotal study readout - but it's just the beginning. We are continuing to advance our pipeline of novel drug candidates in other disease indications and look forward to sharing additional successful data readouts in the future."

  • Benzinga

    The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 7) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) (announced ...

  • GlobeNewswire

    Applied Therapeutics Announces Positive Topline Results of Pivotal Phase 2 ACTION-Galactosemia Study of AT-007 in Galactosemia Patients

    NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) --  Applied Therapeutics Inc. (APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced positive topline results from the Pivotal Phase 2 portion of the ACTION-Galactosemia study of AT-007, a central nervous system (CNS) penetrant Aldose Reductase inhibitor, in adult Galactosemia patients. ACTION-Galactosemia is a double-blind placebo-controlled trial evaluating safety and pharmacokinetics of AT-007 in healthy volunteers, as well as safety, pharmacokinetics, and biomarker effects in adult Galactosemia patients over 28 days of once daily oral dosing. The key biomarker outcome of the study was reduction in galactitol, an aberrant toxic metabolite of galactose, formed by Aldose Reductase in Galactosemia patients.

  • Is Applied Therapeutics, Inc. (APLT) A Good Stock To Buy?
    Insider Monkey

    Is Applied Therapeutics, Inc. (APLT) A Good Stock To Buy?

    Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

  • GlobeNewswire

    Applied Therapeutics to Ring Nasdaq Closing Bell on December 17th

    Applied Therapeutics Inc. (APLT), announced today that Shoshana Shendelman, Ph.D., Founder, Chief Executive Officer and Chair of the Board, will ring the Nasdaq Closing Bell on Tuesday, December 17, 2019, at 4:00 p.m. ET. The ceremony will take place at the Nasdaq MarketSite, 4 Times Square, in New York. A live stream of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live.

  • GlobeNewswire

    Applied Therapeutics Announces Presentation of Pre-Clinical Data Highlighting AT-001 for Treatment of Diabetic Cardiomyopathy at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

    Applied Therapeutics Inc. (APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the presentation of data at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles (December 4-7, 2019) on AT-001, a novel, potent and selective aldose reductase inhibitor (ARI) in Phase 3 clinical development for Diabetic Cardiomyopathy (DbCM).

  • GlobeNewswire

    Applied Therapeutics Announces Presentations Outlining the Design and Rationale for the ARISE-HF Pivotal Study of AT-001 for Treatment of Diabetic Cardiomyopathy at the 16th Annual Global Cardiovascular Clinical Trialist’s Forum (CVCT)

    Applied Therapeutics Inc. (APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced poster and oral presentations at the 16th Annual Global Cardiovascular Clinical Trialist’s Forum (CVCT) in Washington, D.C. (Embassy of France, December 5-7, 2019) outlining the design and rational for the ARISE-HF study. ARISE-HF is a Phase 3 pivotal study examining effects of AT-001, a novel, potent and selective aldose reductase inhibitor (ARI), on functional capacity (as measured by peak V02) in patients with Diabetic Cardiomyopathy (DbCM) at high risk of progression.

  • GlobeNewswire

    Applied Therapeutics Announces Presentation of Clinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the American Heart Association (AHA) Scientific Sessions 2019

    Applied Therapeutics Inc. (APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the presentation of data at the American Heart Association (AHA) Scientific Sessions 2019 in Philadelphia (November 16-18, 2019) on AT-001, a novel, potent and selective aldose reductase inhibitor (ARI) in Phase 3 clinical development for Diabetic Cardiomyopathy (DbCM). “We are pleased to present additional data at AHA supporting our clinical rationale for development of AT-001 in Diabetic Cardiomyopathy, a fast-moving form of heart failure for which no treatments exist,” said Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics.

  • GlobeNewswire

    Applied Therapeutics Reports Third Quarter 2019 Financial Results

    NEW YORK, Nov. 13, 2019 -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet.

  • GlobeNewswire

    Applied Therapeutics, Inc. Announces Pricing of $20 Million Private Placement of Common Stock

    Applied Therapeutics, Inc. (APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it has entered into a definitive securities purchase agreement, dated as of November 7, 2019, for the sale of its common stock, par value $0.0001 per share (the “Shares”), in a private placement (the “Private Placement”) expected to result in gross proceeds to the Company of approximately $20 million, before deducting placement agent commissions and other offering expenses. The Private Placement is expected to close on or about November 12, 2019, subject to the satisfaction of customary closing conditions.

  • GlobeNewswire

    Applied Therapeutics to Present Data Highlighting AT-007 for the Treatment of Galactosemia at the American Society of Human Genetics (ASHG) 2019 Annual Meeting

    Applied Therapeutics Inc. (APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the Company will give an oral presentation of data at the American Society of Human Genetics (ASHG) 2019 Annual Meeting in Houston (October  15-19) on AT-007, a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in Phase 1/2 development for treatment of Galactosemia. In addition, the Company will host an ASHG Educational  Symposium featuring a panel of Galactosemia experts.

  • Did Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Buy Up More Shares?
    Simply Wall St.

    Did Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Buy Up More Shares?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

  • GlobeNewswire

    Applied Therapeutics to Present Preclinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD)

    “Prevention of cardiac damage in an animal model of disease was an important factor in our early decision to develop AT-001 for Diabetic Cardiomyopathy,” said Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics.